Radioactive labeling of antibody: a simple and efficient method

Area of Science:

• Bioconjugation Chemistry
• Radiopharmaceutical Development
• Immunology

Background:

• Diethylenetriaminepentaacetic acid (DTPA) is a strong chelator used for radiolabeling biomolecules.
• Antibody-based radiopharmaceuticals require efficient and stable conjugation methods for effective targeting.
• Carcinogenic antigen (CEA) is a biomarker for colorectal cancer, making it a target for antibody-based therapies.

Purpose of the Study:

• To develop a simple and efficient method for covalently coupling DTPA to proteins, specifically immunoglobulin G (IgG) antibodies.
• To evaluate the efficacy of DTPA-coupled and indium-111 labeled monoclonal antibodies targeting CEA.
• To assess the in vitro and in vivo targeting capabilities of the developed radiolabeled antibody.

Main Methods:

• Covalent coupling of DTPA to IgG antibodies.
• Radiolabeling of DTPA-coupled antibodies with indium-111 (¹¹¹In).
• In vitro binding assays to assess antigen recognition.
• In vivo biodistribution studies in nude mice bearing human colorectal xenografts.

Main Results:

• A simple and efficient method for DTPA conjugation to proteins was established.
• The ¹¹¹In-labeled monoclonal antibody retained its antigen-binding capability.
• In vivo studies showed significant localization of the radiolabeled antibody in colorectal xenografts (41% injected radioactivity per gram at 24 hours).
• Targeting was superior to control antibody (9%) and radioiodinated antibody (19%).

Conclusions:

• The developed DTPA coupling method is effective for radiolabeling antibodies.
• ¹¹¹In-labeled anti-CEA monoclonal antibody demonstrates specific and efficient tumor targeting in vivo.
• This approach holds promise for developing targeted radiopharmaceuticals for cancer imaging and therapy.